Surgical Management of Obesity in Patients with Morbid Obesity and Nonalcoholic Fatty Liver Disease
被引:11
作者:
Dixon, John B.
论文数: 0引用数: 0
h-index: 0
机构:
Baker IDI Heart & Diabet Inst, Melbourne, Vic 8008, Australia
Monash Univ, Primary Care Res Unit, Melbourne, Vic 8008, AustraliaBaker IDI Heart & Diabet Inst, Melbourne, Vic 8008, Australia
Dixon, John B.
[1
,2
]
机构:
[1] Baker IDI Heart & Diabet Inst, Melbourne, Vic 8008, Australia
[2] Monash Univ, Primary Care Res Unit, Melbourne, Vic 8008, Australia
Metabolic;
Weight loss;
Surgery;
Diabetes;
Hypertension;
Gastric;
Malabsorption;
Mortality;
INDUCED WEIGHT-LOSS;
Y GASTRIC BYPASS;
TYPE-2;
DIABETES-MELLITUS;
BARIATRIC SURGERY;
BILIOPANCREATIC DIVERSION;
AMERICAN ASSOCIATION;
JEJUNOILEAL BYPASS;
COST-EFFECTIVENESS;
HEPATIC STEATOSIS;
MEDICAL THERAPY;
D O I:
10.1016/j.cld.2013.09.011
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Most patients with severe complex obesity presenting for bariatric-metabolic surgery have nonalcoholic fatty liver disease (NAFLD). NAFLD is associated with central obesity, insulin resistance, type 2 diabetes, hypertension, and obesity-related dyslipidemia. Weight loss should be a primary therapy for NAFLD. However, evidence supporting intentional weight loss as a therapy for NAFLD is limited. Bariatric-metabolic surgery provides the most reliable method of achieving substantial sustained weight loss and the most commonly used procedures are associated with reduced steatosis and lobular inflammatory changes, but there are mixed reports regarding fibrosis. Surgery should complement treatment of obesity-related comorbidity, but not replace established therapy.